Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 10/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810837 | 0.93 | P2RY6 (0.48) | P2RY6P2RY2PYGMDNPH1P2RY14 | |
| SCHEMBL18852610 | 0.93 | P2RY6 (0.48) | P2RY6P2RY2PYGMDNPH1P2RY14 | |
| SCHEMBL18287234 | 0.93 | P2RY6 (0.48) | P2RY6P2RY2PYGMDNPH1P2RY14 | |
| SCHEMBL18161337 | 0.86 | PYGM (0.55) | P2RY6PYGMDNPH1 | |
| SCHEMBL18158974 | 0.86 | PYGM (0.55) | P2RY6PYGMDNPH1 | |
| SCHEMBL18161328 | 0.82 | P2RY6 (0.56) | P2RY6P2RY2DNPH1P2RY14 | |
| SCHEMBL18158971 | 0.82 | P2RY6 (0.56) | P2RY6P2RY2DNPH1P2RY14 | |
| SCHEMBL18161336 | 0.81 | P2RY6 (0.66) | P2RY6P2RY2P2RY14 | |
| SCHEMBL18158973 | 0.81 | P2RY6 (0.66) | P2RY6P2RY2P2RY14 | |
| SCHEMBL17210990 | 0.80 | BCHE (0.51) | P2RY6P2RY2PYGMDNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885PYGM 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.